482740

nNOS - PSD-95 Interaction Inhibitor, ZL006

The nNOS - PSD-95 Interaction Inhibitor, ZL006 controls the biological activity of nNOS. This small molecule/inhibitor is primarily used for Cancer applications.

• Synonym(e): nNOS - PSD-95 Interaction Inhibitor, ZL006, 5-(3,5-dichloro-2-hydroxybenzylamino)-2-hydroxybenzoic acid
• Empirische Formel (Hill-System): C₁₄H₁₁Cl₂NO₄
• Molekulargewicht: 328.15
• MDL-Nummer: MFCD20527326
• UNSPSC-Code: 12352200
• NACRES: NA.32

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98% (HPLC)
• Form: solid
• Hersteller/Markenname: Calbiochem^®
• Lagerbedingungen: OK to freeze; protect from light
• Farbe: off-white
• Löslichkeit: DMSO: 50 mg/mL
• Versandbedingung: ambient
• Lagertemp.: −20°C
• SMILES String: Clc1c(c(cc(c1)Cl)CNc2cc(c(cc2)C(=O)O)O)O
• InChI: 1S/C14H11Cl2NO4/c15-8-3-7(13(19)11(16)4-8)6-17-9-1-2-10(14(20)21)12(18)5-9/h1-5,17-19H,6H2,(H,20,21)
• InChIKey: RTEYSQSXRFVKTJ-UHFFFAOYSA-N

Beschreibung

Allgemeine Beschreibung

A cell-permeable and blood-brain barrier-permeant aminosalicylic acid compound that selectively disrupts nNOS and PSD-95 interaction upon NMDAR activation both in primary murine cortical neuron cultures (0.8- and 2.8-fold increase from basal level with or without 30 min 10 uM ZL006 pretreatment before 30 min Glu-Gly stimulation) in vitro and in mice subjected to middle brain artery occlusion (0.4- and 1.9-fold increase from basal level with or without inhibitor pretreatment 15 min before MACO; 1.5 mg/kg i.v.) in vivo without affecting nNOS activity or non-nNOS-mediated NMDAR EPSCs (excitatory postsynaptic currents) in rat hippocampus. Its therapeutic efficacy in limiting ischemia-caused brain tissue damage has been demonstrated in both mice and rats when applied 1 h after blood reperfusion following MACO (60% and 50% reduction of infarction, respectively; 1.5 mg/kg i.v.).

A cell-permeable and blood-brain barrier-permeant aminosalicylic acid compound that selectively disrupts nNOS and PSD-95 interaction upon NMDAR activation both in primary murine cortical neurons (0.8- and 2.8-fold increase from basal level with or without 30 min 10 uM ZL006 pretreatment) in vitro and in mice (0.4- and 1.9-fold increase from basal level with or without inhibitor pretreatment 15 min before ischemia; 1.5 mg/kg i.v.) in vivo without affecting nNOS activity or non-nNOS-mediated NMDAR EPSCs (excitatory postsynaptic currents). Effectively reduce ischemia-caused brain tissue damage in both mice and rats when applied 1 h after blood reperfusion following ishemia (60% and 50% reduction of infarction, respectively; 1.5 mg/kg i.v.).

Verpackung

Packaged under inert gas

Warnhinweis

Toxicity: Regulatory Review (Z)

Rekonstituierung

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Sonstige Hinweise

Zhou, L., et al. 2010. Nature Med.16, 1439.

Rechtliche Hinweise

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3